期刊文献+

FeCl_3损伤小鼠肠系膜小动脉血栓模型的主要影响因素 被引量:1

Main Factors Influencing FeCl_3-Induced Mouse Mesenteric Arteriole Thrombosis Model
下载PDF
导出
摘要 目的:探讨FeCl_3损伤小鼠肠系膜小动脉血栓模型的主要影响因素。方法:通过下腔静脉获取C57Bl/6小鼠全血,用Calcein-AM标记洗涤血小板,将荧光标记的血小板输入受体鼠眼球后静脉窦,进入血液循环系统。实验分为回输血小板数1×10~7、1×10~8和2×10~8 3组;小鼠的周龄分为3-6、6-10和>10周3组;FeCl_3浓度分为6%、12%、24%、48%4个组。血管堵塞时间在10-20 min内,且栓子形成后15 s不脱落即为此模型建立成功。观察回输血小板的数量、小鼠的周龄、FeCl_3的浓度、滤纸片的大小等因素对建立肠系膜小动脉血栓模型的影响。结果:3-6周龄雄鼠血管堵塞时间为16 min,时间相比6-10周的(25 min)短(P<0.05),>10周(38 min)短(P<0.01);1×10~8和2×10~8的回输血小板数血管堵塞时间约15-18min,时间相比1×10~7(30 min)的短;6%和12%的FeCl_3的血管堵塞时间在15-20 min之间,但是24%和48%的FeCl_3一般在10 min以内就会出现血管堵塞现象。结论:FeCl_3损伤的小鼠肠系膜小动脉血栓模型的成功建立受很多因素影响。3-6周龄C57Bl/6雄鼠、回输血小板数(1-2) Objective: To investigate the factors that influence FeCl3-induced mouse mesenteric arteriole thrombosis model. Methods: Platelets were isolated from donor mice and labeled with Calcein-AM. Mice were transfused intravenously with Calcein-AM labeled platelets. The influence of mouse ages(3-6 weeks,6-10 weeks and 10 weeks),transfused platelets counts(1 × 10^7,1 × 10^8 and 2 × 10^8 platelets) and concentrations of FeCl3(6%,12%,24% and48%) on FeCl3-induced thrombosis model were compared. Results: The occlusion time was 16 min for mice aged 3-6 weeks,which was shorter than that for 6 mice aged 6-10 weeks(25 min)(P〈 0. 05) and that for mice aged 10 weeks(38 min)(P 0. 01). The occlusion time resulting from transfusion of 1 × 10^8 and 2 × 10^8 of pletclets was 15-18 min,which was shorter than that of transfusion 1 × 10^7 platelets(30 mins). The occlusion time resulting from transfusion of 6% and 12% FeCl3 was from 15 to 20 min,however the transfusion of 24% and 48% FeCl3 all in all leads to vessel occlusion within 10 min. Conclusion: The factors influencing the success of FeCl3-induced mouse thrombosis model are more. Transfusion of 1 × 10^8 to 2 × 10^8 labeled platelets to 3-6 week-old mice,and 6% to 12% of FeCl3 should be used to induce thrombosis,and the experimental conditions should be optimized for this animal model,therefore,it is easier for us to set up a mouse mesenteric arteriole thrombosis model.
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2017年第5期1504-1508,共5页 Journal of Experimental Hematology
基金 国家自然科学基金重点项目:血小板GPIb-IX结合VWF功能的调控及其信号转导机制研究.项目批准号:81130008
关键词 血小板 FECL3 肠系膜小动脉血栓模型 小鼠 Platelet FeCl3 Mesenteric arteriole thrombosis model mouse
  • 相关文献

参考文献2

二级参考文献16

  • 1廖业敏,程芝俏.氯吡格雷、阿司匹林和低分子肝素联用对急性非ST段抬高心肌梗死的疗效分析[J].中国心血管病研究,2007,5(1):33-35. 被引量:15
  • 2Metha SR, Yusuf S, Peters R J, et al. Effect sofpre treatment with clopidogreland aspirin followed by longterm therapy inpatient sunder going percutaneous coronary interventions: PCI CURE study [ J ]. Lancet, 2009, 358:527-533.
  • 3King SB, Smith SC. 2007 focused update of the ACC/AHA,/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiologe/American Heart Association Task Force on Practice Guideline[J]. J Am Coil Cardiol,2008, 51:172-209.
  • 4Herbert JM, Frehel D, Vallee E, et al. Clopidogrel, a novel antiplatelet and antithromboticagent [ J ]. Cardiovasc Drug Rev, 1993, 11:180-198.
  • 5Caplain H, Donat F, Gaud C, et al. Pharmacokinetics of clopidogrel [J]. Semin Thromb Hemost,1999,25( Suppl2 ):25-28.
  • 6Pollack CV Jr, Braunwald E. 2007 update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST- segment elevation myocardial infarction: implications for emergency department practice[J]. Ann Emerg Med, 2008, 51 (5):591-606.
  • 7Kariyazono H, Nakamura K, shinkawa T, et al. Inhibition Of platelet aggregation and the release of P-selectin cron platelets by cilostazd [J]. Thromb Res, 2001, 101:445-453.
  • 8Wiviott SD, Brannwaid E, Mcabe CH, et al. lntensive oral antlpiatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with pereutane-ous coronary intervention and stenting in the TRITON-TIMI38 trial : a subanalysis of a randomised thai [J]. Lancet, 2008,371 ( 9621 ) : 1353-1363.
  • 9Greenbaum AB, Ohman EM, Gibson CM, et al. Preliminary experience with intravenous P2 Y12 platelet receptor inhibiti on as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial [ J ]. Am Heart J, 2007, 154(4) :702-709.
  • 10Olson JD, Arkin CF, Brandt JT, et al, College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy [ J ] . Arch Patho Lab Med, 1998,122 (9) :782.

共引文献25

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部